{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:41:16Z","timestamp":1794613276092,"version":"4.9.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","award":["1703020"],"award-info":[{"award-number":["1703020"]}],"id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1195919\\u202FN"],"award-info":[{"award-number":["1195919\\u202FN"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1703020\\u202FN"],"award-info":[{"award-number":["1703020\\u202FN"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1195919"],"award-info":[{"award-number":["1195919"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ygyno.2020.08.001","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T07:39:33Z","timestamp":1598341173000},"page":"335-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Splenic 18F-FDG uptake on baseline PET\/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer"],"prefix":"10.1016","volume":"159","author":[{"given":"Emiel A.","family":"De Jaeghere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederiek","family":"Laloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien","family":"Lippens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Van Bockstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathia","family":"De Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Naert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Van Dorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van de Vijver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Tummers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Makar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter J.L.","family":"De Visschere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"De Wever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Amant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore G.","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Vandecasteele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.08.001_bb0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0010","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0015","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","volume":"26","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0020","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/cncr.22974","article-title":"The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival","volume":"110","author":"Kidd","year":"2007","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0025","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ygyno.2012.06.027","article-title":"FDG-PET-based prognostic nomograms for locally advanced cervical cancer","volume":"127","author":"Kidd","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.radonc.2016.08.008","article-title":"Pre- and per-treatment 18F-FDG PET\/CT parameters to predict recurrence and survival in cervical cancer","volume":"120","author":"Leseur","year":"2016","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2010.11.002","article-title":"Prognostic value of metabolic tumor volume measured by FDG-PET\/CT in patients with cervical cancer","volume":"120","author":"Chung","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0040","first-page":"43","article-title":"[(18)F]FDG-PET\/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy","volume":"11","author":"Herrera","year":"2016","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0045","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/MNM.0000000000000516","article-title":"Prognostic value of total lesion glycolysis measured by 18F-FDG PET\/CT in patients with locally advanced cervical cancer","volume":"37","author":"Hong","year":"2016","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0050","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","article-title":"The spleen in local and systemic regulation of immunity","volume":"39","author":"Bronte","year":"2013","journal-title":"Immunity."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0055","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.celrep.2012.08.006","article-title":"Immune tolerance to tumor antigens occurs in a specialized environment of the spleen","volume":"2","author":"Ugel","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0060","doi-asserted-by":"crossref","first-page":"8694397","DOI":"10.1155\/2018\/8694397","article-title":"Using the spleen as an in vivo systemic immune barometer alongside osteosarcoma disease progression and immunotherapy with alpha-PD-L1","volume":"2018","author":"Markel","year":"2018","journal-title":"Sarcoma."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0065","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.trecan.2019.09.009","article-title":"Fibroblasts fuel immune escape in the tumor microenvironment","volume":"5","author":"De Jaeghere","year":"2019","journal-title":"Trends Cancer."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0070","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/s41598-018-35912-4","article-title":"Diffuse splenic FDG uptake is predictive of clinical outcomes in patients with rectal cancer","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196110","article-title":"Prognostic value of diffuse splenic FDG uptake on PET\/CT in patients with gastric cancer","volume":"13","author":"Yoon","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.08.001_bb0080","article-title":"Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma","volume":"53","author":"Pak","year":"2013","journal-title":"Nuklearmedizin Nuclear Med."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208861","article-title":"Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET\/CT for prediction of tumor recurrence in breast cancer","volume":"13","author":"Bang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.08.001_bb0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0095","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0360-3016(02)02705-0","article-title":"Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy","volume":"53","author":"Miller","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0100","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2214\/AJR.10.4679","article-title":"Altered hepatic metabolic activity in patients with hepatic steatosis on FDG PET\/CT","volume":"196","author":"Abikhzer","year":"2011","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0105","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00259-015-3217-0","article-title":"FDG PET\/CT in cancer: comparison of actual use with literature-based recommendations","volume":"43","author":"Petersen","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ygyno.2020.08.001_bb0110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.radonc.2010.07.004","article-title":"Quantitative analysis of PET studies","volume":"96","author":"Weber","year":"2010","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0115","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ijrobp.2008.05.004","article-title":"Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes","volume":"73","author":"Liao","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JTO.0b013e31815e6d6b","volume":"3","author":"Berghmans","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0125","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/IGC.0000000000001207","article-title":"Prognostic impact of pretreatment Fluorodeoxyglucose positron emission tomography\/computed tomography SUVmax in patients with locally advanced cervical Cancer","volume":"28","author":"Cima","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.08.001_bb0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ygyno.2005.10.005","article-title":"F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy","volume":"101","author":"Xue","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0135","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2967\/jnumed.113.133801","article-title":"Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis","volume":"55","author":"Pak","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0140","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current methods to define metabolic tumor volume in positron emission tomography: which one is better?","volume":"52","author":"Im","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ygyno.2020.08.001_bb0145","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJM199904153401509","article-title":"Improved treatment for cervical Cancer\u2014concurrent chemotherapy and radiotherapy","volume":"340","author":"Thomas","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0150","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/IGC.0b013e31828d1ec0","article-title":"Completion surgery after intensity-modulated arc therapy in the treatment of locally advanced cervical cancer: feasibility, surgical outcome, and oncologic results","volume":"23","author":"Tummers","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.08.001_bb0155","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ijrobp.2018.01.092","article-title":"Use of functional magnetic resonance imaging in cervical Cancer patients with incomplete response on positron emission tomography\/computed tomography after image-based high-dose-rate brachytherapy","volume":"102","author":"Kalash","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0160","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0360-3016(99)00228-X","article-title":"Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging","volume":"45","author":"Hatano","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0165","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2014.08.018","article-title":"Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation","volume":"135","author":"Rose","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0170","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1186\/s12885-018-5007-0","article-title":"Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates","volume":"18","author":"Couvreur","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2020.08.001_bb0175","doi-asserted-by":"crossref","first-page":"9523","DOI":"10.1200\/JCO.2016.34.15_suppl.9523","article-title":"Spleen to liver ratio (SLR): Novel PET imaging biomarker for prediction of overall survival after ipilimumab and anti-PD1 in patients with metastatic melanoma","volume":"34","author":"Wong","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0180","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0185","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2018-99-117484","article-title":"The significance of leukocytosis in malignancies: a novel paradigm between leukocytosis, G-CSF, Myeloid-Derived Suppressor Cells and Prognosis","volume":"132","author":"Tavakkoli","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0190","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MNM.0b013e3283595cac","article-title":"Impact of cytokines on diffuse splenic 18F-fluorodeoxyglucose uptake during positron emission tomography\/computed tomography","volume":"34","author":"Pak","year":"2013","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0195","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.7150\/thno.22717","article-title":"Cancer-associated fibroblasts enhance tumor (18)F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT","volume":"8","author":"Shangguan","year":"2018","journal-title":"Theranostics."},{"key":"10.1016\/j.ygyno.2020.08.001_bb0200","first-page":"121","article-title":"Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans","volume":"8","author":"Emami","year":"2015","journal-title":"Cardiovasc. Imaging."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820337574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820337574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:57:56Z","timestamp":1777474676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820337574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0090825820337574"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Splenic 18F-FDG uptake on baseline PET\/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}